BSEM — BIOSTEM TECHNOLOGIES

OTC · Health Care · Biotechnology · CIK 1658678 ·
Last close
$3.91
Market Cap
$66.41M
52W High
$6.09
52W Low
$3.90
ADV30
66,188
Next earnings
2026-08-13
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 10,473,402 9,268,608 1,448,790 761,052 62,392,843 27,158,117 12,376,434
Dec 2024 102,874,353 99,339,786 8,481,578 15,520,498 140,375,727 22,832,706 99,500,195
Sep 2024 18,412,816 14,174,158 9,291,838 6,819,902 104,200,464 14,613,488 81,369,253

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$8,159,468
Investing CF
$-131,331
Financing CF
$191,081
CapEx
$-131,331
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$0.35
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-9,060,009
Inventory
$2,728,981
Receivables
$20,104,929
ST Investments
EBIT TTM
$19,224,703
Pretax Income TTM
$19,039,603
Interest Exp TTM
$204,229
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$37,650,524
EBITDA
$-14,106,755
Free Cash Flow
Enterprise Value
$59,805,428
Total Cash
$13,703,351
Total Debt
$3,279,704
Shares Out
16,984,057
Trailing EPS
$0.88
Book Value
$1.88
ROE
-48.6%
ROA
-9.1%
Div Yield

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 301,827,302 31,200,641 31,884,321 140,375,727 99,500,195 24,476,653
Dec 2023 16,685,405 -7,778,969 -8,482,984 14,560,291 15,904,667 -3,498,960
Dec 2022 6,875,202 -4,681,548 -7,192,949 3,466,433 7,416,385 303,575

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.29

Peers — same industry

TickerNameMarket CapLastDaily %
IMA ImageneBio, Inc. $65.64M $5.82
TCRX TScan Therapeutics, Inc. $65.35M $1.07
ENTX Entera Bio Ltd. $59.56M $1.21
SGMO SANGAMO THERAPEUTICS, INC $76.68M $0.19
TIL Instil Bio, Inc. $55.07M $8.12

News headlines (Yahoo Finance, 1h cache)

BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
2026-05-22 11:00 · Yahoo
BioStem Technologies Q1 Earnings Call Highlights
2026-05-16 03:06 · Yahoo
BioStem Technologies Inc (BSEM) Q1 2026 Earnings Call Highlights: Strategic Acquisition and ...
2026-05-15 05:03 · Yahoo
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
2026-05-14 21:50 · Yahoo
BioStem Technologies Reports First Quarter 2026 Financial Results
2026-05-14 20:05 · Yahoo
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
2026-05-13 21:35 · Yahoo
BioStem Technologies to Present at the 16th Annual LD Micro Invitational
2026-05-12 20:05 · Yahoo
BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
2026-04-30 20:05 · Yahoo
BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer
2026-04-30 11:00 · Yahoo
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
2026-04-08 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.